Journal
EXPERT REVIEW OF RESPIRATORY MEDICINE
Volume 15, Issue 1, Pages 103-115Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/17476348.2021.1843429
Keywords
AECOPD; COPD; exacerbations; skeletal muscle dysfunction; skeletal muscle pathology; skeletal muscle wasting
Categories
Ask authors/readers for more resources
This report reviews the impact of AECOPD on muscle dysfunction in COPD, highlighting the negative effects of AECOPD on muscle function and its underlying mechanisms. Novel treatment options should focus on the enhanced drivers of muscle dysfunction during AECOPD.
Introduction: Muscle impairments are prevalent in COPD and have adverse clinical implications in terms of physical performance capacity, disease burden, quality of life and even mortality. During acute exacerbations of COPD (AECOPDs) the respiratory symptoms worsen and this might also apply to the muscle impairments. Areas covered: This report includes a review of both clinical and pre-clinical peer-reviewed literature of the past 20 years found in PubMed providing a comprehensive view on the role of AECOPD in muscle dysfunction in COPD, the putative underlying mechanisms and the treatment perspectives. Expert opinion: The contribution of AECOPD and its recurrent nature to muscle impairment in COPD cannot be ignored and can be attributed to the acutely intensifying and converging disease-related drivers of muscle deterioration, in particular disuse, systemic inflammation and corticosteroid treatment. The search for novel treatment options should focus on the AECOPD-enhanced drivers of muscle dysfunction as well as on the underlying, mainly catabolic, mechanisms. Considering the impact of AECOPD on muscle function, and that of muscle impairment on the recurrence of exacerbations, counteracting muscle deterioration in AECOPD provides an unprecedented therapeutic opportunity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available